Renal hemodynamics increase dramatically during pregnancy, and pressor responsiveness to exogenous administration of vasoconstrictors is attenuated. We investigated whether or not vasodilatory prostaglandins mediate these phenomena. Trained, chronically instrumented, conscious pregnant rats were used. Control values of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were elevated at midgestation (P < 0.01 and P = 0.05 from prepregnant means, respectively), and effective renal vascular resistance was decreased (P = 0.05). Indomethacin (4.5-6.5 mg/kg body weight IBWI) failed to decrease renal hemodynamics at this stage of pregnancy; in fact, it raised GFR somewhat further (P < 0.05). Systemic pressor responsiveness to bolus administration of norepinephrine and angiotensin II (All) was significantly attenuated by at least gestational day 20. Neither indomethacin (7 mg/kg BW) or meclofenamate (6 mg/kg BW) affected the refractory response. The renal vasculature was also relatively unresponsive to an intravenous infusion of All (5 ng kg-' * min-') during late gestation (day 19); in particular, the fall in ERPF in response to All (16±3%) was markedly less than that observed in the prepregnant condition (34±3%; P < 0.05). Indomethacin (6 mg/kg BW) failed to restore this blunted response, and further attenuation was evident, despite the presence of the inhibitor (gestational day 21). We conclude that vasodilatory prostaglandins do not appear to mediate the rise in renal hemodynamics, and the attenuation of the systemic and renal pressor responsiveness observed during pregnancy, insofar as these phenomena were unaffected by acute cyclooxygenase inhibition in unstressed, conscious rats.
Introduction
Dramatic alterations in renal and cardiovascular hemodynamics occur during gestation in humans. Glomerular 1. Abbreviations used in this paper: All, angiotensin II; BW, body weight; ERPF, effective renal plasma flow; ERVR, effective renal vascular resistance; GFR, glomerular filtration rate; MAP, mean arterial pressure; NE, norepinepprine; PAH, sodium aminohippurate; PG, prostaglandin.
first trimester by as much as 50%; this increment is sustained at least until late pregnancy, when renal hemodynamics may decline toward prepregnant values (1) (2) (3) . Cardiac output also rises dramatically (4) , and blood pressure falls by -10 mmHg (5) . Taken together, these data indicate that renal and systemic vascular resistance are decreased during much of gestation.
We have recently reported that the chronically instrumented, conscious rat demonstrates alterations of renal hemodynamics and blood pressure during pregnancy which resemble those observed in human gestation (6) . (Our study corroborated several, but not all, previous investigations performed in various strains of acutely prepared, pregnant rats [for pertinent reviews, see References 6 and 7] .) The application of a chronically prepared, conscious animal preparation to the study of renal and cardiovascular function during pregnancy provides three distinct advantages: (a) The perturbations of renal hemodynamics and of the hormonal and cardiovascular systems, which are brought about by anesthesia and surgical stress (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) as well as by alterations of plasma volume (19, 20) , are avoided. This advantage may be particularly apropos to pregnancy, in which the underlying physiology is radically altered from the nonpregnant condition; that is, even before an experimental variable of interest is implemented, the anesthesia and surgical stress may have affected pregnant and nonpregnant animals differently, such that the latter no longer serves as an adequate control. (b) Each animal can be used as her own control-the same rat can be studied longitudinally (before, during, and after pregnancy). (c) Inasmuch as the changes in renal hemodynamics and blood pressure observed in the chronically instrumented, conscious pregnant rat resemble those of human gestation (6) , it is possible that results regarding mechanisms can be extrapolated to humans.
Several investigators have postulated a role for vasodilating prostaglandins (PGs) in the control of systemic vascular resistance and blood pressure during pregnancy (21, 22) . Pedersen and co-workers (23) have demonstrated an increase in urinary excretion of PGE2 during human pregnancy, as assessed by radioimmunoassay. Using gas chromatography-mass spectrometry, Goodman and associates (24) observed a rise in urinary excretion of two metabolites of PGI2. Venuto and Donker (25) and Paller (26) have reported increases of urinary PGE2 excretion in pregnant rabbits and rats, respectively. In the present study, we tested whether or not PGs serve as vasodepressor agents in pregnancy. Our study, carried out in chronically instrumented, conscious rats, included (a) the effects of cyclooxygenase inhibition on GFR, ERPF, and effective renal vascular resistance (ERVR); (b) the change in mean arterial pressure (MAP) produced by bolus administration ofangiotensin II (AII) and norepinephrine (NE), before and after inhibition of prostaglandin synthesis; and (c) the influence of an intravenous infusion of AII on renal hemodynamics and MAP, before and after cyclooxygenase inhibition. The general approach, therefore, was to assess the contribution ofPGs (ifany) to the control ofrenal and cardiovascular function during pregnancy by acute interruption ofPG synthesis. Clarification ofthe role that these hormones may have in normal pregnancy could facilitate investigation of the pathogenesis of preeclampsia. Indeed, several investigators (23, 24, 27) have postulated that a relative deficiency of vasodilating PGs may be causative.
Methods

Animal preparation
Female Long-Evans rats (Charles River Breeding Laboratories, North Wilmington, MA) fed a normal diet (Charles River RMH 3000 formula) were used. They were -14 wk old at the beginning of the study. All animals underwent training in the experimental cage (28) prior to surgery (3-4 h/d for at least 7 d). Details of the surgical preparation and postoperative care have been previously described (6, 28) . Aseptic technique was employed, and animals were allowed 7-10 d of recovery from surgery before the first experiment was run.
Experimental procedures
Effects of indomethacin on renal function. Animals were studied twice before mating with 4 d allowed between studies. After conception (day 1 of gestation was documented by the presence of spermatozoa in the vaginal lavage), the same rats were again examined on gestational days 12 and 20 (total gestation being 22 d (ranging from 4.5 to 7.0 mg/kg BW) and meclofenamate (6 mg/kg BW) employed in these studies effect significant inhibition of renal prostaglandin production (29) (30) (31) . For verification, urine samples obtained from a few of the studies performed in the very first experimental procedure described above were analyzed for urinary PGE2 and PGF2. excretion (32) . Indomethacin reduced the urinary excretion of PGE2 and/ or PGF2. by >90% (n = three observations in two nonpregnant rats, and n = two observations in two pregnant rats). In a day-14 pregnant rat, meclofenamate decreased the urinary excretion of PGE2 by 74%.
All (5-ILE All or Hypertensin II; Sigma Chemical Co.) was freshly prepared every 2 mo as stock solution in 5% dextrose (100 tg/ml), and kept in 1.0-ml aliquots at -20°C. Final (35) . A value of P < 0.05 was taken to be significant.
Results
Effects ofindomethacin on renalfunction. Indomethacin did not alter MAP or GFR in nonpregnant rats (Table I) . ERPF was decreased, and ERVR (MAP-5/ERBF) increased, slightly-both by -5% (P < 0.05 and P < 0.1, respectively). Time-control studies (Table II) performed in nonpregnant rats showed no significant changes in any of these variables, although ERPF tended to decrease, and ERVR to increase by -5%. Thus, indomethacin had little, if any effect on renal hemodynamics. (The percent changes of ERPF and ERVR between indomethacin and timecontrol studies were not significant-both P > 0.1.) As shown in Table I , the urinary excretion rate of sodium (UNa * V) and fractional excretion of sodium (CNd1CIn) were apparently augmented by indomethacin. Examination of the timecontrol studies (Table II) , on the one hand, shows that similar increments occurred. Indomethacin, therefore, most likely had no overall effect on renal handling of sodium. (The percent changes of UNa. V and CNS1CIn between indomethacin and timecontrol studies were not significant-both P > 0.1.) On the other hand (Table I) , the drug did effect significant decrements in po- Finally, whereas urinary flow rate ( V) increased in time control studies (Table II , P = 0.05), no such increment was observed in the experiments involving administration of indomethacin (Table I) .
Of the 21 nonpregnant rats tested with indomethacin, nine were subsequently mated, and examined on gestational days 12 and 20. The prepregnant values for renal function and MAP before and after indomethacin (Fig. I A and B ; Table III) were not different from those obtained from the larger group of 21 rats discussed above. As we observed previously (6), base-line values of GFR and ERPF were significantly elevated on gestational day 12 (Fig. I A) , when compared to prepregnant means (P < 0.01 and P = 0.05, respectively), and ERVR was decreased ( Fig. 1 B, P = 0.05) . In order to further verify that this increment in renal hemodynamics is specific to pregnancy, time-control studies were performed in nonpregnant animals over a period of 5-40 d after surgical preparation (Table IV) . Analysis of variance showed a significant main effect of time only on BW (P < 0.001).
Indomethacin did not decrease renal hemodynamics during midgestation. In fact, GFR was enhanced further (P < 0.05). The tendency for ERPF to fall, and ERVR to rise, as seen in time-control studies (Table II) , and in experiments using indomethacin in nonpregnant rats (Table I ; Figs. 1 A and B) was not observed on gestational day 12. By day 20, GFR had returned towards prepregnant levels, and ERPF was actually less than, and ERVR greater than, prepregnant means (both P < 0.05; Fig. 1 A and B) . Although indomethacin did not alter GFR at this stage of pregnancy, it did seem to further depress ERPF, and augment ERVR, albeit not significantly. These changes were not statistically different from those obtained in the prepregnant or time-control studies.
Data of renal sodium and potassium excretion from the pregnant rats are portrayed in Table III . (The prepregnant data are similar to those presented in Table I , which were discussed above.) On gestational days 12 and 20, UNa* V and CNaSCII, did not increase significantly after indomethacin, as we had observed in the nonpregnant rats that received the inhibitor (Tables I and  IIi) , and in the time-control studies (Table II) . After administration of indomethacin, potassium excretion decreased on both gestational days.
Effects of All and NE on blood pressure before and after indomethacin or meclofenamate. The response ofMAP to boluses of All and NE before and after administration of indomethacin (7 mg/kg BW) is shown in Fig. 2 A. In the nonpregnant condition, the inhibitor did not potentiate the blood pressure response by the vasoconstrictors. The control dose-response curves for All and NE were generally unchanged during pregnancy until day 20, when the curve was shifted significantly downward. Indomethacin failed to affect the attenuated responses obtained on gestational day 20. During the postpartum period, they spontaneously returned to prepregnant values. That cyclooxygenase inhibition does not influence the downward shift of the dose-response curves for All and NE observed on gestational day 20, was corroborated by studies using meclofenamate (6 mg/kg BW). Shown in Fig. 2 B is the response of MAP to boluses of All and NE before and after this inhibitor. The increments in MAP were significantly less on day 20 of pregnancy. Analysis of variance showed a significant main effect of pregnancy for All and NE, P < 0.001 and < 0.005, respectively. These attenuated responses were unaffected by meclofenamate (no significant main effect of inhibitor was demonstrated).
To improve the accuracy ofour study, we administered only one dosage of All (25 ng/kg BW) and NE (200 ng/kg BW), each in triplicate, before and after meclofenamate (rather than infusing different dosages, each only once, so as to obtain a complete dose-response curve). Using this protocol (Fig. 2 C) , the pressor responses to All and NE were significantly decreased by gestational days 20 and 12, respectively. Note that the curves connecting the mean values obtained after giving meclofenamate are essentially parallel to or overlapping the control curvesindicating that cyclooxygenase inhibition did not affect the blunted response to exogenous vasoconstrictors observed during pregnancy. Again, analysis of variance showed no significant main effect of inhibitor.
Presented in Table V is the pressor responsiveness in acutely prepared, virgin and pregnant rats (gestational days 15-16), which had recovered for 60 min from implantation of catheters under ether anesthesia. The initial control responses (60-110 min after surgery) of these animals were significantly less than those for chronically instrumented rats (all P < 0.05; see Fig. 2 C for comparison). Overall, acutely prepared, pregnant rats demonstrated lower responses than virgins (P < 0.05 for NE and AII). Meclofenamate appeared to significantly augment the control responses in pregnant and virgin animals-a finding clearly different from results obtained in chronically prepared rats (Fig. 2 A-C) . The increase in the responses, however, may not have been due solely to meclofenamate. They tended to recover spontaneously, particularly in virgin animals (Table V) : control pressor responses obtained 120-140 min postimplantation of catheters were greater than those elicited 60-1 10 min after surgical preparation. Finally, the inhibitor did not restore responses of virgin and pregnant rats to the same level-the latter were still somewhat attenuated.
Effects of AII on renal hemodynamics before and after indomethacin. In that systemic pressor responsiveness was blunted during late gestation, we tested whether or not the renal circulation also developed an attenuated pressor response. In nonpregnant animals (Table VI) , All infusion elicited a significant rise in MAP and ERVR, and fall in GFR and ERPF (all P < 0.01). The reduction in ERPF exceeded that of GFR (34±3% and 15±2%, respectively). During late gestation, increments of MAP and ERVR in response to All were less than those observed in nonpregnant animals. The decrement in ERPF and GFR were also attenuated. These attenuated responses observed during late pregnancy (day 19) were not restored by indomethacin. In fact, they tended to be further depressed on gestational day 21, despite administration of indomethacin.
Discussion
Based on these studies performed in conscious unstressed rats, we are unable to support the hypothesis that PGs function as vasodepressor agents in the renal and systemic vasculature during pregnancy. That is, acute inhibition of cyclooxygenase with indomethacin and/or meclofenamate did not reverse: (a) the rise in GFR and ERPF, and fall in ERVR; (b) the attenuated systemic pressor response to an infusion of All, or boluses of All and NE; and (c) the attenuated renal vascular response to an All infusion.
To our knowledge, only one other group of investigators addressed the potential role of PGs in the control of renal hemodynamics during pregnancy (25) . In that study, administration of indomethacin for 3 d (10 mg* kg-' * d-') to rabbits failed to prevent the gestational rise in creatinine clearance. In our study, acute administration of indomethacin (4.5-6.5 mg/kg BW) to pregnant rats (gestational day 12) did not decrease GFR or ERPF, or increase ERVR toward prepregnant levels ( Fig. 1  A and B) .2 Paradoxically, GFR was further elevated (P < 0.05), and the tendency for ERPF to fall, and ERVR to rise, as demonstrated by nonpregnant animals that received indomethacin (Table I ; Fig. 1 A and B) and by time-control studies (Table II), was not observed. Because we did not perform time-control studies during midgestation, we cannot exclude the possibility 2. Naden and co-workers (77) that similar findings would have occurred in the absence of indomethacin. Alternatively, other potential effects of the inhibitor (36, 37) could have caused the additional increment of GFR. During late pregnancy (day 20), renal hemodynamics may have shown a dependency on vasodilating PGs (Fig. 1 A and B) , in that indomethacin seemed to depress ERPF and to raise ERVR more precipitously. But these changes were not statistically different from those observed in the same animals before conception (Fig. I A and B) , or in time-control studies (Table II) .
Briefly, our data obtained from nonpregnant rats (see Results; Tables I and II) confirm previous investigations in conscious, unstressed animals (30, 38-41) that cyclooxygenase inhibition has little or no effect on renal hemodynamics. Because the excretion of sodium increased in nonpregnant animals, whether or not indomethacin was given (Tables I-III) , cyclooxygenase inhibition apparently did not effect renal handling of sodium. (The excretion ofsodium increased spontaneously, probably because we were infusing solutions that contained the ion, albeit at a relatively low rate [<3.5 Aeq/min].) The influence of cyclooxygenase inhibitors on sodium excretion is controversial (30, 41, 42; for a pertinent review, see Reference 40) . Because the increment in sodium excretion was absent during pregnancy (Table III) , indomethacin may be antinatriuretic in this condition. Most likely, however, time-control studies performed in pregnant animals would reveal the same finding. Because extracellular water is expanded (by as much as 50%; Reference 43), the infusion would have less impact. Additionally, pregnancy is a relatively sodium-avid condition, in that the ion is accumulated throughout its course (43) sodium was retained. The observation that urine flow increased in time-control studies (Table II; probably as a result of our infusion of 24 ,ul/min), and was unchanged in nonpregnant and pregnant rats given indomethacin (Tables I and II) , suggests that cyclooxygenase inhibition is antidiuretic. This conclusion agrees with some, but not all previous reports (30, 42; for a pertinent review, see Reference 40) . Finally, the pronounced antikaliuretic effect ofthe inhibitor that we observed (Tables I and II) disagrees with several previous investigations in conscious animals (30, 40, 42) . On the other hand, infusion of PGs into conscious dogs promoted kaliuresis (44) , and a strong correlation exists between urinary PG and K+ excretion in some conditions (45, 46) . Indomethacin may promote antikaliuresis indirectly, by inhibition of the renin-angiotensin aldosterone axis (37) . The attenuated systemic pressor response to exogenous vasoconstrictors that develops during pregnancy has been observed in many species (26, (47) (48) (49) (50) (51) (52) , present study). The mechanism(s) is not clearly defined, and prereceptor, receptor, and/or postreceptor phenomena could contribute. For example, increased production of enzymes that inactivate the administered vasoconstrictors (53) or enhanced sensitivity of the baroreflex (54) could result in apparent attenuated vascular responsiveness; down-regulation, decreased affinity, or prior occupancy of receptors by high circulating levels of hormone could effect a blunted response (49); alteration of vessel wall constituents (55), (52) have demonstrated that an essential fatty acid-deficient diet enhanced the All pressor response in pregnant rabbits. The drawback of their study is that the effects of the diet were not examined in nonpregnant rabbits-it is possible that the pressor response would have been enhanced by a similar degree. As well, surgical stress of tracheal intubation, and the anesthetic agent may have rendered the pressor response PG-dependent in those pregnant animals maintained on a regular diet-not unlike the PG dependency of renal blood flow which develops in dogs as a consequence of surgical preparation and/or anesthesia (for pertinent reviews, see References 16 and 40) .
Our results conflict with those of Paller (26), who reversed the attenuated pressor response of rat pregnancy with meclofenamate. The major difference between his study and ours lies in the preparation; whereas we used trained, chronically instrumented, conscious rats that were allowed 7-10 d of recovery from surgery, Paller employed untrained, conscious rats given 60 min for recovery from implantation of catheters under ether anesthesia. In an attempt to reproduce Paller's work, we followed his protocol (26) . As demonstrated in Table V , control pressor responsiveness ofpregnant rats (gestational days [15] [16] was less than that of virgins, and after meclofenamate, it was significantly enhanced in pregnant animals (P < 0.05). This much of the study is in accordance with the data of Paller. We further showed that a similar potentiation occurred in virgin rats, although pressor responsiveness tended to recover spontaneously, particularly in the virgin animals (Table V) . Because ether anesthesia and surgical stress dramatically increase plasma renin activity (1 1, 14) , and noradrenaline levels (18) , much ofthe attenuation may have been secondary to prior occupancy ofAll and NE receptors, or even receptor down-regulation (60) by high levels ofcirculating hormones. A degree of spontaneous recovery would then be expected to occur, as the hormone levels decreased. We have previously shown that renal hemodynamics are also perturbed for at least 2-3 h after implantation of catheters under ether anesthesia (10) . Moreover, because All and NE may augment PG synthesis (61) (62) (63) , pressor responsiveness could become PGdependent in this acute rat preparation. A further possibility is that PG production may be differentially activated by stress in pregnant and virgin animals: in an effort to defend a low vascular resistance during stressful conditions, thereby ensuring adequate blood flow and oxygen delivery to the fetoplacental unit, pregnant animals may recruit vasodilatory substances, such as PGs, to a greater degree. (The above discussion of All and NE applies to arginine vasopressin, which Paller also used to elicit pressor responses.) Venuto and colleagues have provided the most convincing data that PGs modify the pressor response during pregnancy, at least in rabbits (50, 51) . Meclofenamate was given acutely to conscious, pregnant rabbits (48-72 h were allowed for recovery from surgery), and partial restoration of the pressor response to NE was observed (compare their Figs. 1 and 2 in Reference 50). The same inhibitor significantly decreased the dose of All required to raise diastolic pressure by 20 mmHg in pregnant rabbits, although the amount of All needed to achieve this rise in blood pressure was not significantly different from that in nonpregnant animals before meclofenamate was given (51) . Mc- Laughlin and associates (64) demonstrated that the threshold concentration required to raise blood pressure by 4 mmHg was increased for All, but not for barium chloride in the perfused hind limb of pregnant rabbits. Hart (65, 66) has shown that aortic arterial and portal venous strips from pregnant rats display a reduction in barium-induced increments of tension. These studies (50, 51, (64) (65) (66) , including our own, perhaps suggest that pressor responsiveness in pregnant rabbits and rats are modified by different mechanisms.
Our investigations suggest that the renal vasculature also develops an attenuated pressor response to an intravenous infusion of All during late gestation (Table VI) . This finding is consonant with studies ofpulmonary vascular reactivity in pregnant rats (67) and dogs (68) , in which the response to hypoxia and to infusions of All or PGF2. was depressed. In the pregnant dogs (68) , meclofenamate failed to reverse the blunted hypoxic pressor response. Likewise, in our experiments, indomethacin failed to restore the attenuated effect of All on ERPF observed during late gestation (Table VI) . Based on these data (Table VI, present study; see also Reference 68) we suggest that mechanism(s) other than the vasodilatory action of PGs offset the imposed vasoconstrictor stimuli.
It seems unlikely that the amount ofindomethacin employed in our experiments was insufficient to inhibit cyclooxygenaseat least in the kidney. (The arguments which follow, also apply to meclofenamate.) First, the dosage is consistent with (or exceeds) those reported to have significantly reduced urinary excretion of PGE2 and/or PGF2, (29) (30) (31) . Secondly, urine analyzed from our experiments demonstrated a significant reduction in the excretion rates of PGE2 and/or PGF2. in both nonpregnant and pregnant animals (>90% for indomethacin and 74% for meclofenamate; see Methods). Of course, we cannot be sure whether the drug inhibited synthesis by glomeruli, and the adjacent microvasculature (presumably the major sites that regulate renal hemodynamics), or by the systemic vasculature, because these compartments probably do not contribute greatly to urinary levels-the urinary excretion of PGE2 and PGFu. may predominantly reflect renal medullary production (69 [at least in nonpregnant rats]). Some investigators have reported circulating levels of PGs during pregnancy (21, 22, 25, 70) , which perhaps originate from the fetoplacental unit (22, 70) . These PGs could then gain access to the urine (61), presumably by filtration and secretion. Because indomethacin can cross the placenta in late, but probably not midgestation in the rat (71, 72) (73, 74) . They are thought to have short half-lives in the circulation (75, 76) , and interpretation of measurements obtained from plasma or serum is complicated by the fact that blood collection can lead to artifactual production of large amounts of hormone (75, 76).
In conclusion, our studies fail to support the hypothesis that prostaglandins serve as vasodepressor agents in the renal and systemic vasculature during rat gestation. In order to explain the vasorelaxation observed in pregnancy, other potential mechanisms require investigation.
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